Nimodipine
Back to searchMolecule Structure
Scientific Name
Nimodipine
Description of the Drug
Nimodipine is a calcium channel blocker used to improve neurological outcomes in patients with subarachnoid hemorrhage due to a ruptured intracranial aneurysm.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00393
http://www.drugbank.ca/drugs/DB00393
Brand Name(s)
Nimodipine, Nimotop, Nymalize
Company Owner(s)
Thepharmanetwork Llc, Sun Pharmaceutical Industries Inc, Sofgen Pharmaceuticals, Bionpharma Inc, Azurity Pharmaceuticals Inc, Heritage Pharmaceuticals Inc Dba Avet Pharmaceuticals Inc, Bayer Pharmaceuticals Corp
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Mineralocorticoid receptor | SINGLE PROTEIN | ANTAGONIST | CHEMBL1994 |
| Voltage-gated L-type calcium channel | PROTEIN FAMILY | BLOCKER | CHEMBL2095229 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL34041 | ||
| PharmGKB | PA450633 | ||
| Human Metabolome Database | HMDB0014537 | ||
| DrugBank | DB00393 | ||
| PubChem: Thomson Pharma | 14831516 | ||
| PubChem | 4497 | ||
| Mcule | MCULE-4717687158 | ||
| LINCS | LSM-1659 | ||
| BindingDB | 50101971 | ||
| EPA CompTox Dashboard | DTXSID5023370 | ||
| DrugCentral | 1937 | ||
| ChemicalBook | CB1398087 | ||
| Guide to Pharmacology | 2523 | ||
| rxnorm | NIMOTOP | NYMALIZE | NIMODIPINE |
| PubChem: Drugs of the Future | 12013716 | ||
| KEGG Ligand | C07267 | ||
| ChEBI | 7575 |
